Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children
Authors:
- R.B WomerRWR.B Womer
- R.T DallerRDR.T Daller
- J.Gallagher FentonJFJ.Gallagher Fenton
- J.S MiserJMJ.S Miser
- 1 January 2000
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 36 (1) , 87-94
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia.Journal of Clinical Oncology, 1997
- Recombinant human erythropoietin reduces the need for erythrocyte and platelet transfusions in pediatric patients with sarcoma: A randomized, double-blind, placebo-controlled trialThe Journal of Pediatrics, 1996
- Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.Journal of Clinical Oncology, 1996
- Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancerAnnals of Oncology, 1995
- Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization.Proceedings of the National Academy of Sciences, 1994
- Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivoNature, 1994
- Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients on Combination ChemotherapyJNCI: Journal of the National Cancer Institute, 1993
- Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients With Osteogenic Sarcoma and Ewing's SarcomaJNCI: Journal of the National Cancer Institute, 1991
- Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcomaMedical and Pediatric Oncology, 1990
- The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancerBritish Journal of Cancer, 1989